HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 PatientsReport as inadecuate




HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients - Download this document for free, or read online. Document in PDF available to download.

Gastroenterology Research and Practice - Volume 2015 2015, Article ID 975695, 7 pages -

Research Article

Gastroenterology Unit, San Paolo Hospital, Via Genova 38, 17100 Savona, Italy

Department of Endocrinology, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy

Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy

Received 14 December 2014; Accepted 4 February 2015

Academic Editor: Roberto César P. Lima-Júnior

Copyright © 2015 Alessandro Grasso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Methods. 75 consecutive noncirrhotic, nonobese, and nondiabetic patients with genotype 1 chronic hepatitis C treated with peginterferon alpha 2a plus ribavirin were evaluated. HOMA-IR, serum leptin, and BMI were measured in all patients at baseline and at weeks 12 and 48, whereas viral load was measured at the same time points and then 24 weeks after the end of treatment. Results. HOMA-IR was significantly associated with both BMI and leptin at baseline. During peginterferon plus ribavirin treatment, there was a significant reduction of HOMA-IR at weeks 12 and 48 from baseline and 0.048, resp. in patients who achieved an early viral load decay EVR, a trend not observed in patients who not achieved EVR. No variations during treatment were observed regarding BMI and leptin irrespective of EVR. Conclusion. The early reduction of HOMA-IR but not of BMI and leptin during antiviral treatment in noncirrhotic, chronic hepatitis C genotype 1 patients who achieved EVR suggests a viral genesis of insulin resistance in patients with nonmetabolic phenotype.





Author: Alessandro Grasso, Federica Malfatti, Gabriella Andraghetti, Simona Marenco, Chiara Mazzucchelli, Sara Labanca, Renzo Corder

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents